ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

U.S. FDA opens door to using biomarkers to approve Alzheimer’s drugs

by Ryan Cross
February 26, 2018 | APPEARED IN VOLUME 96, ISSUE 9

Credit: National Institute on Aging/NIH
Many Alzheimer’s drugs in development target plaques of amyloid-β (brown) or tangles of tau (blue).

The U.S. Food & Drug Administration released five guidance documents on Feb. 15 regarding drug development for neurological conditions. The documents clarify FDA’s current thinking on clinical trial design and how to measure a drug’s effectiveness. One notable change is a proposal to evaluate Alzheimer’s drug effectiveness by measuring biomarkers in trial patients before dementia becomes apparent. That’s an important shift for pharmaceutical companies, because hundreds of Alzheimer’s drug trials—most of which recruited people with more advanced disease and looked for cognition improvement—have ended in failure. The failed drugs frequently targeted the two main proteins implicated in the disease: amyloid-β, which forms plaques among brain cells, and tau, which clumps into tangles inside cells. Some companies think the drugs could work if given to people before dementia sets in, but such trials could take decades to run. Instead, companies could look at levels of plaques or tangles to more quickly evaluate whether a drug is working. The idea is contentious, however, because it is still unclear if removing or preventing plaque and tangle formation will prevent Alzheimer’s.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment